Impact of OCT1 and CYP2D6 Genotypes on Pharmacokinetics of Berberine in Healthy Volunteers

NACompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

July 19, 2022

Primary Completion Date

November 20, 2022

Study Completion Date

December 31, 2022

Conditions
Pharmacokinetic Study in Healthy Volunteers
Interventions
DIETARY_SUPPLEMENT

Berberine

A single dose of 1000 mg berberine in two capsules will be administered with 250 ml of still water in the overnight fasting condition. A total of 12 blood samples will be taken at defined time points (baseline, 1; 1.5; 2; 3; 4; 5; 6; 8; 10; 24; 48 h). At each time point, blood will be collected in 2x 7.5 ml tubes for collecting serum and plasma samples to determine berberine, its metabolites and biomarkers of OCT1 transport and CYP2D6 enzymatic activity

Trial Locations (1)

17489

University Medicine Greifswald, Institute of Pharmacology, Greifswald

All Listed Sponsors
lead

University Medicine Greifswald

OTHER